Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer

What Was Tested

This randomized controlled trial paper looks at Leuprolide and Goserelin.

Androgen deprivation therapy (ADT) is widely employed in the management of advanced prostate cancer, with luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide and goserelin being common options.

Who Took Part

The abstract describes 174 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, men only.

A prospective, randomized, controlled study was conducted with 174 patients diagnosed with prostate cancer and treated with ADT for 12 months.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Leuprolide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The timeline in the abstract includes 12 months.

Serum PSA and testosterone levels, lipid and glycemic profiles, and adverse events were monitored.

Genetic analyses were performed to identify mutations in the TP53, BRCA1, BRCA2, and ATM genes.

What Was Measured

Topics PubMed links to this paper include Leuprolide, Goserelin, Prostatic Neoplasms, Prostate-Specific Antigen, Antineoplastic Agents, Hormonal, Testosterone and Androgen Antagonists.

The authors tagged it with the keywords adverse events, androgen deprivation therapy, genetic profile, luteinizing hormone-releasing hormone (LHRH) agonists and prostate cancer.

What This Means in Plain Language

The paper is a randomized study of Leuprolide and Goserelin in 174 patients over 12 months.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (The Canadian journal of urology), a journal based in United States.

More context: the Leuprolide compound page and the Goserelin compound page, all human trials.